Craig Fox

Craig Fox is an Operating Partner at Oxford Science Enterprises, with over 20 years of drug discovery and development expertise, including vast experience as a research scientist managing initial target selection through to Phase 2 clinical studies.

At OSE Craig has helped to find, fund and build several start-ups including Kesmalea, ISOgenix, MatchBio and Kodiform and is also a Board Director for Endlyz Therapeutics.? Prior to OSE, Craig was at C4X Discovery where he was Chief Scientific Officer and an Executive Board Member for more than six years, guiding its transition from a technology-based company to a therapeutics business. Craig has also worked at a number of biotechnology companies supporting multiple financing deals, the creation and management of strategic collaborations and licensing deals with Pharma. Craig holds a PhD in Respiratory Medicine from Birmingham University and a first-class Biochemistry degree from the University of Surrey.